![Track B Slides.pptx [Read-Only]](https://static.fdocuments.us/doc/165x107/627184c01e229a34aa0efd7c/track-b-read-only.jpg)
TRACK B RAPPORTEUR REPORT
27
Washington D.C., USA, 22-27 July 2012 www.aids2012.org TRACK B RAPPORTEUR REPORT JOSE R ARRIBAS on behalf of…
description
TRACK B RAPPORTEUR REPORT. JOSE R ARRIBAS on behalf of …. WHEN TO START. HPTN-052. STARTING > 350 vs 500 better than < 350 ?. Grinsztejn . THLBB05. WHAT TO START. SPRING-2. Raffi . THLBB04. - PowerPoint PPT Presentation
Transcript of TRACK B RAPPORTEUR REPORT
Washington D.C., USA, 22-27 July 2012www.aids2012.org
TRACK B RAPPORTEUR REPORT
JOSE R ARRIBAS on behalf of…
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Washington D.C., USA, 22-27 July 2012www.aids2012.org
WHEN TO START
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HPTN-052
STARTING > 350 vs <250 (229). AIDS + Non-AIDS: No differenceAIDS: better (TB) >500 better than < 350 ?
Grinsztejn. THLBB05
Washington D.C., USA, 22-27 July 2012www.aids2012.org
WHAT TO START
Washington D.C., USA, 22-27 July 2012www.aids2012.orgRaffi. THLBB04
SPRING-2
Washington D.C., USA, 22-27 July 2012www.aids2012.orgRaffi. THLBB04
No difference by NUCs or high viral loadsNo INI mutations nor NRTI mutations were detected through 48 weeks on DTGNo withdrawals due to renal events Small increase in creatinine due to blockade of Cr secretion in DTG arm
DOLUTEGRAVIR QD NEW OPTION
NO RESISTANCE “UNPRECEDENTED”
Washington D.C., USA, 22-27 July 2012www.aids2012.org
DOLUTEGRAVIR POSSIBLE FOR
TEEN/KIDS(RALTEGRAVIR ALSO)
“CHEWING” RAL
Hazra. TUAB0203
Washington D.C., USA, 22-27 July 2012www.aids2012.orgGallant. TUAB0103
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Gallant. TUAB0103
No development of PI resistance in either group. Similar lipidsExpected small increase in serum creatinine (≈0.1 mg/dL) Iin the COBI armLow and comparable discontinuation rates due to renal AE Similar discontinuation rates due to bilirubin-related AEs
COBI AND RITONAVIR
CAN YOU SPOT THE DIFFERENCES?
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HOW TO SWITCH
Washington D.C., USA, 22-27 July 2012www.aids2012.orgPalella. TUAB0104
Lower rate of virologic non-suppression in FTC/RPV/TDF (17/17 with transmitted K103N suppressed)Switching: improvement in fasting lipids and 10-year Framingham Risk Score
FTC/RPV/TDFStrong/simple switch option
Washington D.C., USA, 22-27 July 2012www.aids2012.org
In these three ARV trials < 15%
females. We need to do better!
Washington D.C., USA, 22-27 July 2012www.aids2012.org
RESISTANCE
Washington D.C., USA, 22-27 July 2012www.aids2012.org
0% 5% 10% 15% 20% 25% 30% 35% 40%0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
Eastern AfricaSouthern AfricaWestern and Central AfricaSouth-East Asia RegionWestern Pacific Regionother
Antiretroviral therapy coverage: % of people living with HIV receiving ART
Prev
alen
ce o
f NN
RTI r
esis
tanc
e m
u-ta
tions
: % o
f gen
otyp
es
Transmitted HIVDR (WHO surveys) Relationship between transmitted resistance to NNRTI and
ART coverage
MORE COVERAGE,
MORE OPTIONS, more (different)
resistanceBertagnolio. TUAB0305
Washington D.C., USA, 22-27 July 2012www.aids2012.org
TB
Washington D.C., USA, 22-27 July 2012www.aids2012.org
EFAVIRENZ C min % < 400 copies/mL
Luetkemeyer. TUAB0104
Do not support weight-based increase of EFV
during rifampin treatment
Washington D.C., USA, 22-27 July 2012www.aids2012.org
RAL new option for ART during TB treatment.
Optimal RAL dose yet to be defined
N. De Castro. THLBB01
Washington D.C., USA, 22-27 July 2012www.aids2012.org
HCV
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Lo Re. WEAB0102
Despite ART, HIV/HCV pts had higher risk of
hepatic decompensation than HCV-monoinfected pts
Washington D.C., USA, 22-27 July 2012www.aids2012.org
AGING/COMORBIDITIES
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Schouten. THAB0205
Comorbidities more prevalent amongst
HIV-positives compared to uninfected controls
of similar age
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Schouten. THAB0205
Death rates in people with access to care
AIDS still leading cause of death
Non AIDS cancers leading non-AIDS cause
of death
Washington D.C., USA, 22-27 July 2012www.aids2012.org
ADJUSTING TO TIME
Washington D.C., USA, 22-27 July 2012www.aids2012.org
ADJUSTING TO SPACE
